US 2023/0054595 A1 · NOVEL DRUGGABLE TARGETS FOR THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AND METHODS FOR DIAGNOSIS AND TREATMENT USING THE SAME

Abstract

Compositions and methods for the management and treatment of inflammatory disorders including SLE are disclosed.

Dependent claims

A method for alleviating inflammatory disease symptoms in a patient in need thereof, comprising;

a) identifying in a nucleic acid containing biological sample from said patient, an inflammatory disease GWAS causal variant in a gene which is indicative of the presence of, or increased risk for, inflammatory disease;
b) treating said patient with an effective amount of at least one agent which targets said gene harboring said causal variant, thereby alleviating inflammatory disease symptoms.

Dependencies are inferred from the claim text.

Facts

Application

17/787,433Filed 18 Dec 2020

Priority

18 Dec 2019

Published

23 Feb 2023

Term ends

Not estimatedThe source records don’t support an estimate.

C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
A61K 31/444
Containing further heterocyclic ring systems: containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
A61K 45/06
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00: mixtures of active ingredients without…
A61P 37/00
Drugs for immunological or allergic disorders

Compositions and methods for the management and treatment of inflammatory disorders including SLE are disclosed.

Dependent claims

A method for alleviating inflammatory disease symptoms in a patient in need thereof, comprising;

a) identifying in a nucleic acid containing biological sample from said patient, an inflammatory disease GWAS causal variant in a gene which is indicative of the presence of, or increased risk for, inflammatory disease;
b) treating said patient with an effective amount of at least one agent which targets said gene harboring said causal variant, thereby alleviating inflammatory disease symptoms.

Dependencies are inferred from the claim text.